Shares of Lantheus Holdings (NASDAQ: LNTH) soared 5.15% in pre-market trading on Wednesday, following the company's strong fourth-quarter 2024 financial results and upbeat outlook for the year ahead.
The radiopharmaceutical company reported a 10.5% year-over-year increase in revenue to $391.1 million for the fourth quarter, exceeding analysts' expectations of $377.1 million. Adjusted earnings per share (EPS) came in at $1.59, surpassing the consensus estimate of $1.54.
Lantheus' blockbuster radiodiagnostic product, PYLARIFY, continued to drive growth, with sales reaching $1.06 billion for the full year 2024, marking a significant milestone as the first radiodiagnostic to achieve blockbuster status.
For the full year 2025, the company provided revenue guidance in the range of $1.545 billion to $1.61 billion, slightly below analysts' expectations of $1.605 billion. However, Lantheus' adjusted EPS guidance of $7.00 to $7.20 exceeded the consensus estimate of $6.95.
Lantheus also highlighted its strategic initiatives to enhance its radiopharmaceutical leadership, including the acquisition of Life Molecular Imaging Ltd. and Evergreen Theragnostics Inc. These acquisitions are expected to diversify the company's portfolio and expand its pipeline with late-stage and early-stage assets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。